NCT05738057View on ClinicalTrials.gov

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2026

Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Camrelizumab

200mg on day1 of every 3 weeks, starting on day1 of cycle1

DRUG

Gemcitabine Injection

1000mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1

DRUG

Cisplatin injection

25mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1

DRUG

Cisplatin-Eluting Beads

used for D-TACE

PROCEDURE

D-TACE

TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.

Trial Locations (1)

Unknown

RECRUITING

The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Hua Li

OTHER